312.79  -10.71 (-3.31%)		07-09 16:00
Open: 378.49 High: 380 Volume: 5,838,723		Pre. Close: 323.49999 Low: 311.0001 Market Cap: 41,761(M)

Short term
Mid term
Targets	6-month :	396.14	1-year :	443.83
Resists	First :	339.16	Second :	380
Pivot price	300.07
Supports	First :	273.1	Second :	227.22
MAs	MA(5) :	318.18	MA(20) :	296.71
	MA(100) :	309.23	MA(250) :	373.86
MACD	MACD :	6.3	Signal :	2.3
%K %D	K(14,3) :	79.8	D(3) :	88.6
RSI	RSI(14): 65.9
52-week	High :	495.54	Low :	273.1

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ALNY ] has closed below upper band by 15.1%. Bollinger Bands are 85.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	325.5 - 326.46	326.46 - 327.53
Low:	313.85 - 315.03	315.03 - 316.34
Close:	321.41 - 323.2	323.2 - 325.2

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.

Thu, 09 Jul 2026
BridgeBio hits 52-week high on late-stage trial setback for Astra/ Ionis (update) - Seeking Alpha

Thu, 09 Jul 2026
Pfizer, Alnylam, BridgeBio gain after late-stage trial setback for Astra/Ionis - MSN

Thu, 09 Jul 2026
Alnylam Pharmaceuticals: An Unexpected Rival Trial Failure Improves The Core TTR Franchise Outlook - Seeking Alpha

Thu, 09 Jul 2026
ALNY Stock Rallies As RNAi Expansion And AI Deals Deepen - StocksToTrade

Thu, 09 Jul 2026
Thursday's Stock Market Winners and Losers: Alnylam Pharmaceuticals (ALNY) Jumps 18% as AstraZeneca (AZN) Plunges - Blockonomi

Thu, 09 Jul 2026
S&P 500 Futures Climb In Premarket Trading; Alnylam Pharmaceuticals, BridgeBio Pharma Lead - Moomoo

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	134 (M)
Shares Float	133 (M)
Held by Insiders	0.1 (%)
Held by Institutions	102 (%)
Shares Short	5,440 (K)
Shares Short P.Month	5,400 (K)

EPS	3.99
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	8.06
Profit Margin	12.5 %
Operating Margin	23 %
Return on Assets (ttm)	10 %
Return on Equity (ttm)	90.3 %
Qtrly Rev. Growth	96.4 %
Gross Profit (p.s.)	25.91
Sales Per Share	32.13
EBITDA (p.s.)	6.04
Qtrly Earnings Growth	0 %
Operating Cash Flow	715 (M)
Levered Free Cash Flow	205 (M)

PE Ratio	80.2
PEG Ratio	0.5
Price to Book value	39.7
Price to Sales	9.95
Price to Cash Flow	59.76

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.